CN102549434A - 叶酸盐靶向的诊断和治疗 - Google Patents

叶酸盐靶向的诊断和治疗 Download PDF

Info

Publication number
CN102549434A
CN102549434A CN2010800434602A CN201080043460A CN102549434A CN 102549434 A CN102549434 A CN 102549434A CN 2010800434602 A CN2010800434602 A CN 2010800434602A CN 201080043460 A CN201080043460 A CN 201080043460A CN 102549434 A CN102549434 A CN 102549434A
Authority
CN
China
Prior art keywords
patient
tumor
treatment
folate
tumour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800434602A
Other languages
English (en)
Chinese (zh)
Inventor
C.P.利蒙
R.梅斯曼
D.摩尔金斯特恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Priority to CN201510160314.2A priority Critical patent/CN104857534A/zh
Publication of CN102549434A publication Critical patent/CN102549434A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2010800434602A 2009-07-31 2010-07-30 叶酸盐靶向的诊断和治疗 Pending CN102549434A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510160314.2A CN104857534A (zh) 2009-07-31 2010-07-30 叶酸盐靶向的诊断和治疗

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23059509P 2009-07-31 2009-07-31
US61/230595 2009-07-31
US34644410P 2010-05-19 2010-05-19
US61/346444 2010-05-19
US35102210P 2010-06-03 2010-06-03
US61/351022 2010-06-03
PCT/US2010/043992 WO2011014821A1 (en) 2009-07-31 2010-07-30 Folate-targeted diagnostics and treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510160314.2A Division CN104857534A (zh) 2009-07-31 2010-07-30 叶酸盐靶向的诊断和治疗

Publications (1)

Publication Number Publication Date
CN102549434A true CN102549434A (zh) 2012-07-04

Family

ID=43529728

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800434602A Pending CN102549434A (zh) 2009-07-31 2010-07-30 叶酸盐靶向的诊断和治疗
CN201510160314.2A Pending CN104857534A (zh) 2009-07-31 2010-07-30 叶酸盐靶向的诊断和治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510160314.2A Pending CN104857534A (zh) 2009-07-31 2010-07-30 叶酸盐靶向的诊断和治疗

Country Status (13)

Country Link
US (2) US20120128587A1 (https=)
EP (1) EP2460013A4 (https=)
JP (1) JP2013501224A (https=)
KR (1) KR20120050462A (https=)
CN (2) CN102549434A (https=)
AU (1) AU2010278734A1 (https=)
BR (1) BR112012002064A2 (https=)
CA (1) CA2769754A1 (https=)
IL (1) IL217744A0 (https=)
IN (1) IN2012DN01708A (https=)
NZ (1) NZ598145A (https=)
RU (1) RU2012105641A (https=)
WO (1) WO2011014821A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109475558A (zh) * 2016-05-25 2019-03-15 普渡研究基金会 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法
CN121337736A (zh) * 2025-12-16 2026-01-16 临沂市人民医院 多柔比星与免疫调节剂共载脂质体的制备及其协同抗肿瘤用途

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
KR20130140032A (ko) 2010-11-12 2013-12-23 엔도사이트, 인코포레이티드 암을 치료하는 방법들
SG194458A1 (en) * 2011-04-12 2013-12-30 Endocyte Inc Solid pharmaceutical composition
EA201590783A1 (ru) 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
US10188738B2 (en) 2013-10-16 2019-01-29 Université Libre de Bruxelles Formulations useful in the treatment of proliferative diseases affecting the respiratory tract
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3533473A3 (en) 2013-11-14 2019-12-18 Endocyte, Inc. Compounds for positron emission tomography
WO2015077303A1 (en) 2013-11-19 2015-05-28 Purdue Research Foundation Patient selection method for inflammation
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
EP3242556A1 (en) * 2015-01-11 2017-11-15 Endocyte, Inc. Cancer imaging agent
IL237525A (en) 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
WO2018182776A1 (en) * 2016-03-29 2018-10-04 Endocyte, Inc. Folate conjugate for use in targeting tumor associated macrophages
WO2017192863A1 (en) 2016-05-04 2017-11-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071754A2 (en) * 2004-12-23 2006-07-06 Purdue Research Foundation Positron emission tomography imaging method
CN101111267A (zh) * 2004-12-21 2008-01-23 尼克塔治疗亚拉巴马公司 稳定的聚合物巯基试剂
CN101175757A (zh) * 2005-03-16 2008-05-07 恩多塞特公司 蝶酸及其缀合物的合成和纯化

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069159A2 (en) * 2003-01-27 2004-08-19 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
ATE460668T1 (de) * 2005-03-30 2010-03-15 Purdue Research Foundation Verfahren zur prognose von brustkrebs mittels quantifizierung von zellulären folat vitamin rezeptoren
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
MX2009004555A (es) * 2006-10-25 2009-05-11 Schering Corp Metodos de tratamiento de cancer de ovario.
CN101784565B (zh) * 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101111267A (zh) * 2004-12-21 2008-01-23 尼克塔治疗亚拉巴马公司 稳定的聚合物巯基试剂
WO2006071754A2 (en) * 2004-12-23 2006-07-06 Purdue Research Foundation Positron emission tomography imaging method
CN101175757A (zh) * 2005-03-16 2008-05-07 恩多塞特公司 蝶酸及其缀合物的合成和纯化

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHER P. LEAMON等: "Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC 140 and EC145", 《INT. J. CANCER》 *
DOWNS等: "A Prospective Randomized Trial of Thalidomide with Topotecan Compared With Topotecan Alone in Women With Recurrent Epithelial Ovarian Carcinoma", 《CANCER》 *
RONALD E. FISHER等: "Exploratory Study of 99mTc-EC20 Imaging for Identifying Patients with Folate Receptor-Positive Solid Tumors", 《J NUCL MED》 *
YAP等: "Beyond chemotherapy: targeted therapies in ovarian cancer", 《NATURE REVIEWS CANCER》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109475558A (zh) * 2016-05-25 2019-03-15 普渡研究基金会 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法
CN114903890A (zh) * 2016-05-25 2022-08-16 普渡研究基金会 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法
CN121337736A (zh) * 2025-12-16 2026-01-16 临沂市人民医院 多柔比星与免疫调节剂共载脂质体的制备及其协同抗肿瘤用途

Also Published As

Publication number Publication date
KR20120050462A (ko) 2012-05-18
AU2010278734A1 (en) 2012-02-23
IL217744A0 (en) 2012-03-29
WO2011014821A1 (en) 2011-02-03
CA2769754A1 (en) 2011-02-03
NZ598145A (en) 2014-10-31
CN104857534A (zh) 2015-08-26
EP2460013A1 (en) 2012-06-06
IN2012DN01708A (https=) 2015-06-05
JP2013501224A (ja) 2013-01-10
BR112012002064A2 (pt) 2017-05-09
US20140140925A1 (en) 2014-05-22
RU2012105641A (ru) 2013-09-10
US20120128587A1 (en) 2012-05-24
EP2460013A4 (en) 2013-04-03

Similar Documents

Publication Publication Date Title
CN102549434A (zh) 叶酸盐靶向的诊断和治疗
AU2017268291B2 (en) PET-imaging immunomodulators
CN110312517A (zh) 促黄体激素释放激素受体(lhrh-r)缀合物及其用途
JP2017503763A (ja) Ｇｃｃ発現細胞を撮像するための化合物及び組成物
EP2795317B1 (en) Composition for use in a method for cancer selection
US20250009916A1 (en) Combination therapy for treating lung cancer
US20240050597A1 (en) Radiolabelled alpha-v beta-3 and/or alpha-v beta-5 integrins antagonist for use as theragnostic agent
US20240131206A1 (en) Peptide receptor radionuclide therapy
CN118891066A (zh) 用于癌症治疗和成像的复合物
HK1172952A (en) Folate-targeted diagnostics and treatment
EP3597224B1 (en) Pigment-coupled mannosyl serum albumin complex and lymph node-probing composition comprising same
WO2026088112A1 (en) Combination therapies with ar-degrading agents and psma-targeting radioligands
WO2023164769A1 (en) Radiopharmaceutical and methods
CN114989256A (zh) 一种放射性同位素标记的分子探针及其制备方法与应用
WO2025251001A1 (en) N-(2-(-2-cyano-4-fluoropyrrolidin-1-yl)-2-oxoethyl)quinoline-4-carboxamide tracer and uses in pet imaging
CN118742332A (zh) 放射性药物和方法
AU2015203646A1 (en) Folate-targeted diagnostics and treatment
DE112011105133T5 (de) Octapeptid zur Herstellung von radiopharmazeutischen Mitteln, das auf dessen Basis hergestellte Arzneimittel und Diagnoseverfahren von Somatostatin-Rezeptor exprimierenden Tumoren

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1172952

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120704

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1172952

Country of ref document: HK